Dihydrocodeine

An opioid analgesic used for pain management

Dihydrocodeine
INN
Drug class
Routes of administration	Oral, subcutaneous, intramuscular
Pregnancy category
Bioavailability	20% (oral)
Metabolism	Hepatic
Elimination half-life	3.5–5 hours
Excretion	Renal
Legal status
CAS Number	125-28-0
PubChem	5284543
DrugBank	DB01551
ChemSpider	4447628
KEGG	D07880

Dihydrocodeine is a semi-synthetic opioid analgesic prescribed for the relief of moderate to severe pain. It is also used as an antitussive to suppress cough. Dihydrocodeine is a hydrogenated derivative of codeine, and it is available in various formulations, including tablets, elixirs, and injectable solutions.

Pharmacology

Dihydrocodeine acts primarily as an agonist at the mu-opioid receptor, which is responsible for its analgesic effects. It also has some affinity for the delta-opioid receptor and kappa-opioid receptor, contributing to its overall pharmacological profile. The drug is metabolized in the liver by the cytochrome P450 enzyme system, primarily CYP2D6, into active metabolites such as dihydromorphine.

Mechanism of Action

The analgesic effects of dihydrocodeine are mediated through its action on the central nervous system, where it binds to opioid receptors and inhibits the transmission of pain signals. This results in an increased pain threshold and altered perception of pain.

Medical Uses

Dihydrocodeine is indicated for the management of moderate to severe pain, particularly when other analgesics such as paracetamol or nonsteroidal anti-inflammatory drugs (NSAIDs) are insufficient. It is also used as a cough suppressant in certain formulations.

Dosage and Administration

The dosage of dihydrocodeine varies depending on the formulation and the severity of the condition being treated. It is typically administered orally, but can also be given via subcutaneous or intramuscular injection. The usual adult dose ranges from 30 mg to 60 mg every 4 to 6 hours as needed for pain.

Side Effects

Common side effects of dihydrocodeine include nausea, vomiting, constipation, drowsiness, and dizziness. As with other opioids, there is a risk of respiratory depression, particularly at higher doses or in combination with other central nervous system depressants.

Precautions

Dihydrocodeine should be used with caution in patients with a history of substance abuse, respiratory disorders, or hepatic impairment. It is classified as a Schedule II controlled substance in the United States, indicating a high potential for abuse and dependence.

Related Pages

• Opioid analgesic
• Codeine
• Pain management
• Cough suppressant

• 

  Dihydrocodeine skeletal structure

• 

  Dihydrocodeine 3D animation